The International Registry of Blastic Plasmocytoid Dendritic Cell Neoplasm (BPDCN) shared a post on LinkedIn:
“Rare diseases should not be excluded from meaningful evidence generation simply because large randomized trials are difficult.
In BPDCN, progress depends on international collaboration. Multicenter registries make it possible to transform limited single-center experience into a broader real-world understanding of presentation, treatment, and outcomes.
The BPDCN International Registry was established to support exactly this kind of global collaboration and data collection in a rare and aggressive hematologic malignancy.
Every case matters, and additional centers interested in contributing to this growing effort are warmly welcome to connect.”
Other articles about BPDCN on OncoDaily.